Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Nov;66(5):667-73.
doi: 10.1111/j.1365-2125.2008.03278.x.

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up

Ciro Costagliola  1 , Ugo Cipollone, Michele Rinaldi, Michele della Corte, Francesco Semeraro, Mario R Romano
Affiliations
Clinical Trial

Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up

Ciro Costagliola et al. Br J Clin Pharmacol. 2008 Nov.

Abstract

Aims: Neovascular glaucoma (NVG) represents one of the most severe forms of secondary glaucoma, caused by a number of ocular and systemic conditions, which share the common element of retinal ischaemia/hypoxia that initiates the subsequent release of angiogenesis factors, with consequent development of new abnormal vessels through the ciliary body. The aim was to examine the potential efficacy and safety of intravitreal injection of bevacizumab (IVB) (Avastin) in the treatment of NVG in patients who had already undergone the standard retinal ablative procedure.

Methods: This was a prospective pilot trial. Clinical data of 26 eyes from 23 patients, including diagnosis, visual acuity, iris fluorescein angiography stage and intraocular pressure (IOP), were collected. Three injections of bevacizumab were scheduled for each recruited eye at 4-week intervals from the start. All investigations were repeated the day before the IVB (1.25 mg/0.05 ml) and at the 1-, 3-, 6-, 9- and 12-month follow-up.

Results: Regression of corneal oedema together with significant pain reduction was achieved in all eyes already after the first IVB, without any noteworthy improvement of visual acuity. At the end of the scheduled protocol (three IVB), regression of iris neovascularization was documented in all patients, together with significant improvement of visual acuity. The IOP reduction from baseline ranged from 30 to 0 mmHg (12.1 +/- 8 mmHg).

Conclusions: Intravitreal bevacizumab, as adjunctive treatment to the standard retinal ablative procedure, seems promising for the management of conditions responsible of retinal ischaemia/hypoxia associated with NVG.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Massive iris neovascularization in two patients with neovascular glaucoma secondary to proliferative diabetic retinopathy. Iris fluorescein angiography shows complete regression of fluorescence leakage at 12 months' follow-up after three intravitreal injections of bevacizumab
Figure 2
Figure 2
Scatter plot of visual acuity at 12 months' follow-up vs. baseline
Figure 3
Figure 3
Scatter plot of intraocular pressure at 12 months' follow-up vs. baseline
See this image and copyright information in PMC

References

    1. Pagenstecher H. Beitrage zur Lehre vom hamorrhagischen Glaukom. Graefes Arch Ophthalmol. 1871;17:98–130.
    1. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26:470–85. - PMC - PubMed
    1. Manschot WA. Retinal neovascularization after retinal vaso-obliteration. Frequency-origin-morphology. Doc Ophthalmol. 1983;55:117–20. - PubMed
    1. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–7. - PubMed
    1. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352–68. - PubMed

Publication types

MeSH terms